<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230919059471N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-28</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>The impact of exercise on breast cancer quality of life</public_title>
      <acronym></acronym>
      <scientific_title>The impact of an exercise program on coping self-efficacy and quality of life in breast cancer patients.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73318</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Other design features: In this study, an exercise program includes a 12-week supervised exercise program set by an exercise physiologist. This program will include aerobic exercises, resistance exercises, balance exercises and flexibility exercises in a combined manner and in a regular sequence, taking into account the guidelines of the American College of Sports Medicine (ACSM). The implementation of the exercise program is carried out by an exercise coach who knows the details of exercise in breast cancer. Timing, duration of exercise, intensity of exercise and type of combined exercises are determined separately, Randomization description: Eligible patients are selected using available sampling method and are placed in two exercise and control groups based on simple randomization. Participants are randomized by random assignment through a coin toss into two exercise and usual care groups. The face of the coin (i.e. lion = control group), and the back of the coin (i.e. line = intervention group) are considered, Blinding description: In this study, the medical personnel (doctors, nurses, physiotherapists, etc.) who are responsible for the care of the patients, and those who analyze the data and evaluate the outcome, and those who prepare the draft of the article; They are blinded to study group allocation.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Breast Cancer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: intervention group: exercise group; They receive an exercise program including 12-week supervised exercises developed by a sports physiologist, 3 days a week for 50-60 minutes. This program will include aerobic exercises, resistance exercises, flexibility exercises and balance exercises. Aerobic exercise class consists of three parts: warm-up, aerobic exercises, and cool-down. Intervention 2: Control group: Patients in the control group only do their normal physical activities and are provided with educational brochures about routine care.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, such as the information related to the main outcome or the like, can be shared.

When:
The access period starts 6 months after the results are published.

To whom:
It will be available only to researchers working in academic and scientific institutions.

Conditions:
Researchers working in academic and scientific institutions at the rank of assistant professor and higher.

Where to obtain:
Islamic Azad University, Najafabad branch

How to obtain:
Apply by email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Faridokht Yazdani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Islamic Azad University, Najaf Abad Branch, University Blvd</address>
        <city>Najafabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8514143131</zip>
        <telephone>+98 31 4229 2583</telephone>
        <email>faridokht.yazdani@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Faridokht Yazdani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Islamic Azad University, Najaf Abad Branch, University Blvd.</address>
        <city>Najafabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8514143131</zip>
        <telephone>+98 31 4229 2583</telephone>
        <email>faridokht.yazdani@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients aged 15 to 75 who have been diagnosed with grade I to III breast cancer based on pathology;
Have completed intensive breast cancer treatment (including surgery, chemotherapy, or radiation therapy);
Have the recommendation and permission to participate in the exercises program from the oncologist;
Three weeks after chemotherapy or radiation therapy;
Less than 6 months have passed since chemotherapy or radiation therapy;
Patients should be able to do aerobic and resistance exercises.</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>75 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Having an acute illness or a serious psychiatric illness;
Patients with recurrence or metastasis;
Suffering from other diseases or other continuous treatments such as asthma or osteoporosis and heart disease and blood pressure; Anemia with a decrease in red blood cells;
Ataxia (imbalance in walking);
Patients have not been approved by the oncologist for exercise.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: intervention group: exercise group; They receive an exercise program including 12-week supervised exercises developed by a sports physiologist, 3 days a week for 50-60 minutes. This program will include aerobic exercises, resistance exercises, flexibility exercises and balance exercises. Aerobic exercise class consists of three parts: warm-up, aerobic exercises, and cool-down.</i_keyword>
      <i_keyword>Control group: Patients in the control group only do their normal physical activities and are provided with educational brochures about routine care.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The coping self-efficacy score in the questionnaire has 3 dimensions (stopping emotions and unpleasant thoughts), (problem-oriented strategy), and (receiving support from family and friends). The total scores for each item of that dimension are calculated together. Respondents must answer at least 80% of the scale items. Timepoint: Measuring coping self-efficacy at the beginning of the study (before the start of the intervention) and at the end of the intervention (12 weeks after the start of the study). Method of measurement: Chesney et al. Coping Self-Efficacy Questionnaire (CSES).</prim_outcome>
      <prim_outcome>The quality of life score of breast cancer patients in the QLQ-Br23 questionnaire includes 23 items that are divided into two dimensions. The first dimension includes four functional scales, (sexual function, sexual pleasure, and future perspective); While the second dimension includes four symptom scales (systemic treatment side effects, breast symptoms, arm symptoms, hair loss discomfort). Each item is scored from 1 to 4 points. Scores are converted to a 0-100 score after linear transformation. The highest scores correspond to better performance (except for sexual performance and sexual pleasure). On the other hand, higher scores on the symptom scale dimension are associated with higher persistence of signs and symptoms. Timepoint: Measuring quality of life at the beginning of the study (before the start of the intervention) and at the end of the intervention (12 weeks after the start of the study). Method of measurement: Breast Cancer Quality of Life Questionnaire (EORTC-QLQ-BR23).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Reduce anxiety. Timepoint: End of the intervention (after 12 weeks from the start of the intervention). Method of measurement: Hospital Anxiety and Depression Scale (HADS).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-05</approval_date>
        <contact_name>Islamic Azad University-Najafabad branch</contact_name>
        <contact_address>Islamic Azad University, Najaf Abad branch, University Boulevard Najafabad Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
